FDA Cleared Of Wrongdoing In Generic Xibrom Suit

Law360, New York (July 9, 2012, 7:50 PM EDT) -- A Washington federal judge said Monday that the U.S. Food and Drug Administration had not improperly approved a generic version of Ista Pharmaceuticals Inc.'s post-cataract surgery eye drop medication, Xibrom.

U.S. District Judge James S. Gwin granted the FDA's motion for summary judgment against ISTA, ruling against the pharmaceutical makers' claims that the government had violated the law when it approved an abbreviated new drug application filed by Metrics Inc., which does business as Coastal Pharmaceuticals.

“The court concludes that the FDA did not act unlawfully...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ISTA PHARMACEUTICALS, INC. v. FOOD AND DRUG ADMINISTRATION et al


Case Number

1:11-cv-00907

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

James S. Gwin

Date Filed

May 12, 2011

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.